FDA knocks back Novartis' Certican

5 December 2005

The Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration has called for more safety and efficacy data on Swiss drug major Novartis' Certican (everolimus), so delaying its approval as a prophylactic against acute rejection in heart transplant recipients.

Novartis noted that a majority of the committee members agreed that Certican has demonstrated superior efficacy to a comparator in the prevention of acute rejection, and several members also recognized its potential benefits. However, the majority suggested that more prospective data on the Certican/cyclosporine combination therapy was needed to determine the optimal dosage regimen.

Novartis said that the decision "represents a temporary set-back." It has initiated further clinical studies in heart transplantation using the drug in combination with reduced-dose cyclosporine and therapeutic drug monitoring to supplement the existing clinical registration database from over 3,000 heart and kidney transplant recipients worldwide. Several members of the committee suggested that data from an on-going European post-marketing surveillance study in heart transplantation, which may be available for review in 2007, might address its concerns.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight